vmireavizВестник медицинского института «РЕАВИЗ». Реабилитация, Врач и ЗдоровьеBulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)2226-762X2782-1579РЕАВИЗ10.20340/vmi-rvz.2024.1.CLIN.2vmireaviz-912Research ArticleКлиническая медицинаClinical medicineВыявление мутаций гена EGFR для назначения таргетных препаратовпри немелкоклеточном раке лёгкогоDetection of EGFR gene mutations for prescription of targeted drugs for non-small cell lung cancerhttps://orcid.org/0000-0002-8055-1958ПавловаО. Н.PavlovaO. N.

Павлова Ольга Николаевна - д-р биол. наук, доцент, заведующая кафедрой физиологии с курсом безопасности жизнедеятельности и медицины катастроф,

ул. Чапаевская, д. 89, Самара, 443099

Ol'ga N. Pavlova - Dr. Sci. (Biol.), Associate Professor, Head of the Department of Physiology with the course of Life Safety and Disaster Medicine,

89, Chapaevskaya, Samara, 443099

casiopeya13@mail.ruБукареваО. П.BukarevaO. P.

Букарева Ольга Петровна - врач-онколог, ассистент кафедры физиологии с курсом безопасности жизнедеятельности и медицины катастроф,

ул. Чапаевская, д. 89, Самара, 443099

Ol'ga P. Bukareva - Oncologist, assistant at the Department of Physiology with a course in life safety and Disaster Medicine,

89, Chapaevskaya, Samara, 443099

Самарский государственный медицинский университетРоссияSamara State Medical UniversityRussian Federation2024240220241418690Copyright © Павлова О.Н., Букарева О.П., 20242024Павлова О.Н., Букарева О.П.Pavlova O.N., Bukareva O.P.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestnik.reaviz.ru/jour/article/view/912

Рак лёгких – это один из наиболее распространённых видов онкологических заболеваний, которое встречается как у мужчин, так и у женщин. Эта опухоль занимает лидирующее место среди причин смерти от онкологии, на неё приходится 18,4% от общего числа смертей. Немелкоклеточный рак лёгких является наиболее частым типом рака лёгких, составляющим 85% всех случаев. В его рамках чаще всего встречаются аденокарцинома (30-45%) и плоскоклеточный рак (25–40%). Примерно у 20% пациентов, живущих на территории Российской Федерации и страдающих от немелкоклеточного рака лёгких, наблюдаются мутации гена EGFR. Сигнальные пути EGFR играют важную роль в развитии злокачественных опухолей. Они регулируют прогрессию клеточного цикла, влияют на апоптоз, стимулируют образование новых кровеносных сосудов и усиливают подвижность раковых клеток и их способность к метастазированию. Углубленное понимание фундаментальной биологии редких мутаций EGFR поможет выявить зависимости, специфичные только для этих мутаций. Это знание может быть использовано в разработке терапевтических подходов, направленных на определенные мутации EGFR и их влияние на разные патологии. Результаты проведённых исследований могут способствовать разработке более точных и эффективных методов лечения, которые будут специально ориентированы на конкретные мутации EGFR и их влияние на различные заболевания.

Lung cancer is one of the most common types of cancer that occurs in both men and women. This tumor is the leading cause of death from cancer, accounting for 18.4% of the total number of deaths. Non-small cell lung cancer is the most common type of lung cancer, accounting for 85% of all cases. Within its framework, adenocarcinoma (30-45%) and squamous cell carcinoma (25-40%) are most often found. Approximately 20% of patients living in the Russian Federation and suffering from non-small cell lung cancer have EGFR gene mutations. EGFR signaling pathways play an important role in the development of malignant tumors. They regulate cell cycle progression, influence apoptosis, stimulate the formation of new blood vessels and enhance the motility of cancer cells and their ability to metastasize. An in-depth understanding of the fundamental biology of rare EGFR mutations will help identify dependencies specific to these mutations. This knowledge can be used to develop therapeutic approaches targeting specific EGFR mutations and their impact on various pathologies. The results of these studies may help develop more precise and effective treatments that will specifically target specific EGFR mutations and their impact on various diseases.

EGFRнемелкоклеточный рак лёгкогоEGFRnon-small cell lung cancerReferencesBray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 85 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.214921 Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 85 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492Мазуренко Н.Н., Цыганова И.В., Гагарин И.М., Чуев Ю.В., Мочальникова В.В., Коломейцева А.А., Горбунова В.А. Мутации EGFR и KRAS, важные для таргетной терапии немелкоклеточного рака легких. Молекулярная медицина. 2013;6. URL: https://cyberleninka.ru/article/n/mutatsii-egfr-i-krasvazhnye-dlya-targetnoy-terapii-nemelkokletochnogo-raka-legkih.2 Mazurenko N.N., Tsyganova I.V., Gagarin I.M., Chuev Yu.V., Mochalnikova V.V., Kolomeitseva A.A., Gorbunova V.A. EGFR and KRAS mutations important for targeted therapy of non-small cell lung cancer. Molecular medicine. 2013;6. (In Russ). URL: https://cyberleninka.ru/article/n/mutatsii-egfr-i-krasvazhnye-dlya-targetnoy-terapii-nemelkokletochnogo-raka-legkih.Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019 Aug. 94(8):1623–1640. https://doi.org/10.1016/j.mayocp.2019.01.013. PMID: 31378236.3 Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019 Aug. 94(8):1623–1640. https://doi.org/10.1016/j.mayocp.2019.01.013. PMID: 31378236.Моисеенко В.М., Проценко С.А., Семенов И.И. и др. Применение Ирессы (гефитиниба) в качестве терапии первой линии для лечения неоперабельных аденокарцином лёгкого, содержащих мутацию в гене EGFR. Современная онкология. 2010;12(1):74–80.4 Moiseenko V.M., Protsenko S.A., Semenov I.I., etc. The use of Iressa (gefitinib) as a first-line therapy for the treatment of inoperable lung adenocarcinomas containing a mutation in the EGFR gene. Modern oncology. 2010;12(1):74–80. (In Russ).Shi Y et al. A prospective, molecular epidemiology study of EGFR mutations in asian patients with advanced non-small-cеll lung cаncеr of аdеnocаrcinomа histology (PIONЕЕR). J Thorac Oncol. 2014;9(2):154–162.5 Shi Y et al. A prospective, molecular epidemiology study of EGFR mutations in asian patients with advanced non-small-cеll lung cаncеr of аdеnocаrcinomа histology (PIONЕЕR). J Thorac Oncol. 2014;9(2):154–162.Огнерубов Н.А., Сычeв В.Д., Козловa Н.А., Чaнг В.Л. Молeкулярно-гeнeтический портрeт немeлкоклетoчногo рaка легких в Тамбовской области: региональный опыт. Современная oнколoгия. 2020;22(3):88–93. https://doi.org/10.26442/18151434.2020.3.2003936 Ognerubov N.A., Sychev V.D., Kozlova N.A., Chang V.L. Molecular genetic portrait of non-small cell lung cancer in the Tambov region: regional experience. Modern oncology. 2020;22(3):88–93. (In Russ). https://doi.org/10.26442/18151434.2020.3.200393Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94:1593–611.7 Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94:1593–611.Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J.2000;19:3159–67.8 Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J.2000;19:3159–67.Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2–16.9 Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2–16.Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007;13(12):527–34. https://doi.org/10.1016/j.molmed.2007.10.00210 Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007;13(12):527–34. https://doi.org/10.1016/j.molmed.2007.10.002Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med. 2004;350:2129–39.11 Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med. 2004;350:2129–39.Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513–20.12 Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513–20.Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81.13 Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81.Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.14 Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.Когония Л.М., Губенко М.С., Ашхацава Т.И. Что мы знаем о молекулярно-биологических особенностях EGFR при глиобластомах и немелкоклеточном раке легких? Медицинский совет. 2022;16(9):126–130. https://doi.org/10.21518/2079-701X-2022-16-9-126-13015 Kogonia L.M., Gubenko M.S., Ashkhatsava T.I. What do we know about the molecular biological features of EGFR in glioblastomas and non-small cell lung cancer? Medical advice. 2022;16(9):126–130. (In Russ). https://doi.org/10.21518/2079- 701X-2022-16-9-126-130Carcereny, E., Morán, T., Capdevila, L. et al. The epidermal growth factor receptor (EGRF) in lung cancer. Transl Respir Med. 2015;3(1). https://doi.org/10.1186/s40247-015-0013-z16 Carcereny, E., Morán, T., Capdevila, L. et al. The epidermal growth factor receptor (EGRF) in lung cancer. Transl Respir Med. 2015;3(1). https://doi.org/10.1186/s40247-015-0013-zCappuzzo F, Camidge DR, Varella-Garcia M. Is FISH floating or still swimming in the lung cancer ocean? Ann Oncol 2011;22(3):493–9917 Cappuzzo F, Camidge DR, Varella-Garcia M. Is FISH floating or still swimming in the lung cancer ocean? Ann Oncol 2011;22(3):493–99Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical l ung cancer models. Oncogene. 2008;27(34):4702–11.18 Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical l ung cancer models. Oncogene. 2008;27(34):4702–11.Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S. et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-smallcell lung cancer with postoperative recurrence. J. Clin. Oncol. 2005;23:2513–2520.19 Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S. et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-smallcell lung cancer with postoperative recurrence. J. Clin. Oncol. 2005;23:2513–2520.U.S. Food and Drug Administration. NDA/BLA multi-disciplinary review and evaluation: BLA 761210; RYBREVANT, amivantamab-vmjw. [accessed 2021 Nov 1].20 U.S. Food and Drug Administration. NDA/BLA multi-disciplinary review and evaluation: BLA 761210; RYBREVANT, amivantamab-vmjw. [accessed 2021 Nov 1].Neijssen J, Cardoso RMF, Chevalier KM, Wiegman L, Valerius T, Anderson GM et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem. 2021;296:100641. https://doi.org/10.1016/j.jbc.2021.1006421 Neijssen J, Cardoso RMF, Chevalier KM, Wiegman L, Valerius T, Anderson GM et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem. 2021;296:100641. https://doi.org/10.1016/j.jbc.2021.10064

The authors declare that there are no conflicts of interest present.